any updates on euro trials?, page-6

In the october interview (http://www.tissuetherapies.com/investors/101013%20TIS%20ASX%20Prof%20Keith%20Harding%20Interview.pdf) Prof Harding indicated he would release the data by end Q1 2011. Im not expecting any news until then.

Q: You will lead European trials for VitroGro. What will they entail and when do you expect results?

Keith Harding: The studies that I am going to be leading on are a combination of European and Australian centres where we will be looking at taking patients with venous leg ulcers and evaluating up to 40 patients with two doses, either weekly or twice weekly applications of the active ingredient, to see if that has an impact on healing of those ulcers when those patients are treated with a standard form of graduated compression which is accepted by most people as the cornerstone of managing that particular disease. We do hope that we will be able to show additional benefits in terms of healing or reduction in size of the patients that have been exposed to VitroGro. The practicality and effectiveness of once weekly versus twice weekly are important questions that will need to be answered to determine the utility of this product as it goes forward. We would hope to get the early data available by the end of first quarter 2011. It is important to recognize that undertaking these studies do require a lot of regulatory hurdles to be overcome and then to find suitable patients but we are confident that we will be able to produce data by first quarter 2011.